This cannabinoid bioavailability review looks at a 2025 crossover study testing a nanoemulsified THC/CBD powder against standard oil drops in healthy volunteers. The study found faster absorption and higher cannabinoid exposure with the powder formulation. But cannabinoid bioavailability is not the same as proven clinical benefit, and that distinction matters for patients, providers, and policymakers.
Florida bar offers hemp, THC crafted cocktails, hip decor, new events
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic EdiblesSocial UseDosingBeveragesPharmacokinetics Why This MattersThe emergence of THC-infused beverages in licensed establishments represents a...
DC mayor proposes allowing cannabis drinks – NBC4 Washington
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic EdiblesPolicyDosingPatient SafetyPharmacokinetics Why This MattersCannabis beverages represent a distinct delivery method with different onset...
PharmDs Explain What Happens When You Mix CBD and Alcohol Together
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Drug InteractionsCbdHepatic MetabolismPatient SafetyPharmacokinetics Why This MattersPatients frequently combine CBD with alcohol without understanding...
Cannabis Pharmacokinetics Review: THC, CBD, Dosing
This paper is a broad evidence review of human pharmacokinetic studies on THC and CBD. It helps clarify how route, formulation, food, sex, drug interactions, and patient factors can meaningfully change absorption and exposure. Its main limitation is that it synthesizes heterogeneous studies rather than providing one unified, practice-ready dosing framework.
Study: Clinical evidence review for Cannabidiol
This 2024 paper is a narrative review of cannabidiol, cannabis-derived products, regulation, pharmacology, and clinical use. It offers a useful overview of why purified CBD, commercial extracts, and broader cannabis products should not be treated as interchangeable. Its value is real, but it remains a narrative review, not a new trial, so its conclusions should be read as framing and synthesis rather than definitive proof.
Docs: Driver had THC in blood before striking pedestrian in Blackford County – Fox 59
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic ImpairmentThcLegal MedicinePatient SafetyPharmacokinetics Why This MattersThis case highlights the ongoing clinical and legal challenges...
Cannabinoid Chewing Gum: Promising Concept, Thin Evidence
Despite a long-standing widespread history of chewing gum use in general, there is sparse experience and even less clinical research on the effects and possible clinical value of incorporating cannabidiol or any other cannabinoid in a chewing gum product.
Cannabidiol in Anorexia Nervosa: A Double-Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change.
Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods o…
Behavioural, pharmacokinetic, and genetic evidence of a cannabidiol-oxycodone drug-drug interaction in mice.
This study investigated the interaction between oxycodone and cannabidiol (CBD) on opioid analgesia and pharmacokinetics. We conducted in vivo behavioural st…